JP7880618B2 - CEBP-βアンタゴニストの投与及び使用方法 - Google Patents
CEBP-βアンタゴニストの投与及び使用方法Info
- Publication number
- JP7880618B2 JP7880618B2 JP2022579019A JP2022579019A JP7880618B2 JP 7880618 B2 JP7880618 B2 JP 7880618B2 JP 2022579019 A JP2022579019 A JP 2022579019A JP 2022579019 A JP2022579019 A JP 2022579019A JP 7880618 B2 JP7880618 B2 JP 7880618B2
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- patient
- composition according
- treatment
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Marine Sciences & Fisheries (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063041989P | 2020-06-21 | 2020-06-21 | |
| US202063041986P | 2020-06-21 | 2020-06-21 | |
| US202063041990P | 2020-06-21 | 2020-06-21 | |
| US202063041991P | 2020-06-21 | 2020-06-21 | |
| US202063041988P | 2020-06-21 | 2020-06-21 | |
| US63/041,986 | 2020-06-21 | ||
| US63/041,990 | 2020-06-21 | ||
| US63/041,989 | 2020-06-21 | ||
| US63/041,991 | 2020-06-21 | ||
| US63/041,988 | 2020-06-21 | ||
| US202163172560P | 2021-04-08 | 2021-04-08 | |
| US63/172,560 | 2021-04-08 | ||
| PCT/US2021/038264 WO2021262604A2 (en) | 2020-06-21 | 2021-06-21 | Administration of cebp-beta antagonist and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023531683A JP2023531683A (ja) | 2023-07-25 |
| JP2023531683A5 JP2023531683A5 (cg-RX-API-DMAC7.html) | 2025-01-20 |
| JP7880618B2 true JP7880618B2 (ja) | 2026-06-26 |
Family
ID=79281738
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022579019A Active JP7880618B2 (ja) | 2020-06-21 | 2021-06-21 | CEBP-βアンタゴニストの投与及び使用方法 |
Country Status (17)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119997967A (zh) * | 2022-10-07 | 2025-05-13 | 智慧疗法有限公司 | C/EBP-β拮抗剂和免疫调节剂的使用 |
| WO2024216238A2 (en) * | 2023-04-13 | 2024-10-17 | Sapience Therapeutics, Inc. | Use of beta-catenin antagonist and immunomodulator |
| EP4694911A2 (en) * | 2023-04-13 | 2026-02-18 | Sapience Therapeutics, Inc. | Administration of a beta-catenin antagonist and methods of use |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180237499A1 (en) | 2017-02-20 | 2018-08-23 | Sapience Therapeutics, Inc. | Cell-Penetrating ATF5 Polypeptides and Uses Thereof |
| JP2021508503A (ja) | 2018-01-03 | 2021-03-11 | サピエンス・セラピューティクス・インコーポレーテッド | Atf5ペプチド多様体及びそれらの使用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105228642A (zh) * | 2013-02-22 | 2016-01-06 | 纽约市哥伦比亚大学理事会 | 通过抑制转录因子atf5来抑制肿瘤细胞的组合物和方法 |
| CA2983030A1 (en) * | 2015-04-16 | 2016-10-20 | Alder Biopharmaceuticals, Inc. | Use of anti-pacap antibodies and antigen binding fragments thereof for treatment, prevention, or inhibition of photophobia |
| WO2020033555A2 (en) * | 2018-08-08 | 2020-02-13 | The Trustees Of Columbia University In The City Of New York | Dominant negative cebpb and cebpd proteins and methods of use for decreasing viability of neoplastic cells |
-
2021
- 2021-06-21 AU AU2021297172A patent/AU2021297172B2/en active Active
- 2021-06-21 WO PCT/US2021/038264 patent/WO2021262604A2/en not_active Ceased
- 2021-06-21 CA CA3180559A patent/CA3180559A1/en active Pending
- 2021-06-21 DK DK21828902.3T patent/DK4168033T3/da active
- 2021-06-21 BR BR112022025880A patent/BR112022025880A2/pt unknown
- 2021-06-21 KR KR1020227044587A patent/KR20230027054A/ko active Pending
- 2021-06-21 FI FIEP21828902.3T patent/FI4168033T3/fi active
- 2021-06-21 EP EP21828902.3A patent/EP4168033B1/en active Active
- 2021-06-21 PT PT218289023T patent/PT4168033T/pt unknown
- 2021-06-21 ES ES21828902T patent/ES3066151T3/es active Active
- 2021-06-21 MX MX2022016478A patent/MX2022016478A/es unknown
- 2021-06-21 IL IL299104A patent/IL299104A/en unknown
- 2021-06-21 NZ NZ795026A patent/NZ795026A/en unknown
- 2021-06-21 JP JP2022579019A patent/JP7880618B2/ja active Active
- 2021-06-21 US US18/011,171 patent/US20230218717A1/en active Pending
- 2021-06-21 CN CN202180044276.8A patent/CN115768458A/zh active Pending
-
2022
- 2022-12-05 ZA ZA2022/13167A patent/ZA202213167B/en unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180237499A1 (en) | 2017-02-20 | 2018-08-23 | Sapience Therapeutics, Inc. | Cell-Penetrating ATF5 Polypeptides and Uses Thereof |
| JP2021508503A (ja) | 2018-01-03 | 2021-03-11 | サピエンス・セラピューティクス・インコーポレーテッド | Atf5ペプチド多様体及びそれらの使用 |
Non-Patent Citations (3)
| Title |
|---|
| Cancer Res.,2019年,Vol.79 (13_Supplement), Abstract 2050,https://aacrjournals.org/cancerres/article/79/13_Supplement/2050/634151/Abstract-2050-Cell-penetrating-peptide-ST101 |
| Sapience Therapeutics Announces FDA Acceptance of IND Application for ST101 in Advanced Cancer Indications,2020年06月02日,検索日[令和7年7月29日],URL<https://sapiencetherapeutics.com/sapience-therapeutics-announces-fda-acceptance-of-ind-application-for-st101-in-advanced-cancer-indications/> |
| Sapience Therapeutics Receives United Kingdom Authorization to Initiate a Phase 1/2 Trial of Lead Candidate ST101 in Advanced Cancer Indications,2020年05月07日,検索日[令和7年7月29日],URL<https://sapiencetherapeutics.com/sapience-therapeutics-receives-united-kingdom-authorization-to-initiate-a-phase-1-2-trial-of-lead-candidate-st101-in-advanced-cancer-indications/> |
Also Published As
| Publication number | Publication date |
|---|---|
| ES3066151T3 (en) | 2026-05-11 |
| EP4168033A4 (en) | 2024-06-19 |
| AU2021297172A1 (en) | 2023-01-19 |
| KR20230027054A (ko) | 2023-02-27 |
| EP4168033B1 (en) | 2026-02-25 |
| FI4168033T3 (fi) | 2026-04-07 |
| US20230218717A1 (en) | 2023-07-13 |
| IL299104A (en) | 2023-02-01 |
| PT4168033T (pt) | 2026-03-24 |
| BR112022025880A2 (pt) | 2023-01-10 |
| AU2021297172B2 (en) | 2025-01-30 |
| DK4168033T3 (da) | 2026-05-11 |
| MX2022016478A (es) | 2023-02-01 |
| ZA202213167B (en) | 2026-03-25 |
| CA3180559A1 (en) | 2021-12-30 |
| EP4168033A2 (en) | 2023-04-26 |
| NZ795026A (en) | 2026-03-27 |
| JP2023531683A (ja) | 2023-07-25 |
| WO2021262604A3 (en) | 2022-02-17 |
| WO2021262604A2 (en) | 2021-12-30 |
| CN115768458A (zh) | 2023-03-07 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240618 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240618 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250109 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250804 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20251029 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20251226 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260203 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20260203 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20260515 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20260609 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7880618 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |